Drug Profile
STI 6991
Alternative Names: I-Cell™ COVID-19 cellular vaccine - Sorrento Therapeutics; STI-6991Latest Information Update: 07 Apr 2020
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 31 Mar 2020 Sorrento Therapeutics enters into a research agreement with University of Texas Medical Branch for preclinical testing for COVID-2019 therapeutics
- 25 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (IM)
- 25 Mar 2020 Sorrento Therapeutics announces intention to submit IND to US FDA for COVID-2019 infections (Prevention)